ADCY2 (adenylate cyclase 2) catalyzes the formation of cAMP, a critical secondary messenger in G-protein coupled receptor signaling pathways 1. The enzyme functions downstream of muscarinic acetylcholine receptors and modulates gene expression patterns, including IL-6 production. ADCY2 is highly expressed in the central nervous system and various peripheral tissues, with particularly high expression in testes and muscle 2. Abnormal ADCY2 expression and function are associated with multiple pathological conditions. A bipolar disorder-associated missense variant (Val147Leu) diminishes cAMP production capacity and causes mania-like behavioral phenotypes in mice, responsive to lithium treatment 3. In acute myeloid leukemia, circRNA-mediated ADCY2 downregulation promotes disease progression through impaired cAMP signaling 4. ADCY2 polymorphisms also confer susceptibility to chr5 obstructive pulmonary disease 5 and hepatocellular carcinoma risk in women 6. ADCY2 expression abnormalities have been reported in neurodegenerative diseases (Alzheimer's, Parkinson's), psychiatric disorders (schizophrenia, Tourette syndrome), and neurological conditions including stroke and epilepsy 7. Notably, ADCY2 fusions with TERT were identified in triple wild-type melanomas with clinical implications 8.